Type 3 Von Willebrand International Registries Inhibitor Prospective Study Extended.

Type 3 Von Willebrand International Registries Inhibitor Prospective Study Extended. - 3WINTERS-IPS EXTENDED

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50286

Enrollment

Registered

2014-02-12

Start date

2014-07-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Willebrand disease

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Male and female of any age, including infants, children, adolescents and adults - Informed consent obtained (parents should sign for patients

Exclusion criteria

Exclusion criteria: - VWD3 patients who may not be available for follow-up

Design outcomes

Primary

Measure	Time frame
First part of the study: - Informed consent - Eligibility verification - Patient ID assignment - Demographics - Bleeding history and previous use of blood components - General laboratory test with local assays for VWD3 diagnosis - Family history in the parents and relatives - Blood withdrawal for central laboratory assessment - Mutation analysis in VWD3 - Inhibitor assessment Optional in the relatives: - Informed consent - Historical information - Blood sampling for local laboratory assessment	—

Measure

Time frame

First part of the study: - Informed consent - Eligibility verification - Patient ID assignment - Demographics - Bleeding history and previous use of blood components - General laboratory test with local assays for VWD3 diagnosis - Family history in the parents and relatives - Blood withdrawal for central laboratory assessment - Mutation analysis in VWD3 - Inhibitor assessment Optional in the relatives: - Informed consent - Historical information - Blood sampling for local laboratory assessment

—

Secondary

Measure	Time frame
Second part of the study (4 years): - Bleeding episodes - VWF concentrates - Blood withdrawal for central laboratory assessment only in case of anti-VWF inhibitors	—

Countries

Netherlands

Outcome results